Last reviewed · How we verify
LY2228820
At a glance
| Generic name | LY2228820 |
|---|---|
| Also known as | p38 MAP kinase, ralimetinib |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY2228820 in Participants With Advanced Cancer (PHASE1)
- A Study LY2228820 for Recurrent Ovarian Cancer (PHASE1, PHASE2)
- Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma (PHASE1, PHASE2)
- A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer (PHASE1)
- A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2228820 CI brief — competitive landscape report
- LY2228820 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI